Effects of Glucagon-Like Peptide-1 Receptor Agonists on the Reproductive System: Benefits vs Risks
- Chitre T. [1] ,
- Thao G. [1] ,
- Fadel L. [1] ,
- Rojas E. [1] ,
- Nguyen Fricko M. [1] ,
- Domingo V. [1] ,
- Budginas B. [1] ,
- Carmelo Guerrero L. [1] ,
- Ghatas M. [1] ,
- Arani N. [1] ,
- Tabatabai N. [1] and
- Dr. Pemminati S. [1]
Repository
Description
Abstract
Incretins are hormones that regulate insulin release from the pancreas and encourage a decrease in blood glucose levels. The primary incretins are Glucagon like peptide 1 – receptor agonists (GLP-1 RAs) and gastric inhibitory polypeptide (GIP)1. This systematic review focuses on GLP-1 RAs. GLP-1 RAs have traditionally been used to improve glycemic control in adults with advanced Type 2 Diabetes Mellitus, along with lifestyle modifications. Current guidelines state to improve patient health first with diet and exercise changes and secondarily use GLP-1 RAs as a supplement2. However, GLP-1 RA usage has skyrocketed in the last few years, largely due to the popular trend of using these medications as weight loss options. Thus, it is important to thoroughly study the safety and efficacy of GLP-1 RA usage in various body systems and health conditions so that physicians and patients can make informed decisions. As obesity and insulin resistance are often tied to disorders of the reproductive system, this review aimed to elucidate the specific mechanisms of GLP-1 RA usage on improving conditions including as PCOS in females and infertility in both assigned male at birth (AMAB) and assigned female at birth (AFAB) populations.
Affiliations
- California Health Sciences University College of Osteopathic Medicine